Boswellia Complex
Natural health product licensed in Canada
- Licence holder
- Integria Healthcare (Australia) Pty Ltd
- NPN or DIN-HM
- 80042716
- Status
- Active licence
- Licence date
- 6 June 2013
- Revision date
- 27 June 2021
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Curcuma longa Source : Rhizome Extract : Extract Type TBA Extraction ratio : 25:1 Dry plant equivalent : 2,000 mg Potency : 70.4 mg Curcuminoids | 80 mg | Not calculated |
| Zingiber officinale Source : Rhizome Extraction ratio : 1:2 Dry plant equivalent : 300 mg | 600 mcl | Not calculated |
Non-medicinal ingredients
Croscarmellose de sodium, Hypromellose, Phosphate de calcium, dibasique, Stéarate de magnésium, Dioxyde de silicium, Cellulose microcristalline, Glycolate d'amidon sodique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | minimum: 2 days ; maximum: 4 days |
Uses authorised in Canada
Provides temporary relief of the pain and inflammation of arthritis, osteoarthritis and rheumatism.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have a history of gallstones, biliary tract obstructions and/or stomach ulcers or excess stomach acid; or if you have diabetes or are taking anti-diabetic medication, antacids, or phenprocoumon. Consult a health care practitioner prior to taking this product if you are taking blood-thinning drugs such as warfarin or aspirin or if you have increased risk of haemorrhage. Discontinue use 7 days prior to general anaesthesia. Do not use if you are pregnant or breastfeeding. Consult a health care practitioner if symptoms persist, or worsen.
Source
Official Health Canada record, licence 80042716
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2021. Photograph the packaging to check whether it has changed. Photograph the packaging